BOLTON SECURITIES CORPORATION’s AbCellera Biologics ABCL Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.5K	Buy	+3,013	New	+$10.8K	﹤0.01%	1611

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's ABCL Position: Q1 2026 in Review

BOLTON SECURITIES CORPORATION opened a new position in AbCellera Biologics (ABCL) in Q1 2026: 3,013 shares worth $10.5K. The stake represents ﹤0.01% of the portfolio and ranks #1611 among its holdings.

139 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

BOLTON SECURITIES CORPORATION held 3,013 shares of AbCellera Biologics worth $10.5K as of Q1 2026.
AbCellera Biologics was a new BOLTON SECURITIES CORPORATION position in Q1 2026.
AbCellera Biologics made up ﹤0.01% of BOLTON SECURITIES CORPORATION's portfolio in Q1 2026, its #1611 holding.
139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q1 2026, filed 12 Nov 2026.